| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
37,490,000 |
| Market
Cap: |
26.24(K) |
| Last
Volume: |
125 |
Avg
Vol: |
35,949 |
| 52
Week Range: |
$0.0002 - $0.0044 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Affymax is a biopharmaceutical company in the process of restructuring operations. Co.'s U.S. Food and Drug Administration approved product, OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis, has been recalled. As a result of the voluntary recall of OMONTYS, all marketing activities were suspended and sales were ceased. Co. granted its collaboration partner, Takeda Pharmaceutical Company Limited, a license to OMONTYS.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Orwin John A |
CEO |
• • – |
2012-03-27 |
4 |
OE |
$5.83 |
$47,806 |
D/D |
8,200 |
163,200 |
|
- |
|
| Orwin John A |
CEO |
• • – |
2012-02-02 |
4 |
AS |
$10.00 |
$180,000 |
D/D |
(18,000) |
155,000 |
|
- |
|
| Walker John Peter |
Director |
– • – |
2011-12-19 |
4 |
B |
$6.09 |
$101,364 |
D/D |
16,540 |
16,540 |
2.39 |
- |
|
| Orwin John A |
CEO |
• • – |
2011-08-18 |
4 |
AS |
$4.55 |
$54,600 |
D/D |
(12,000) |
148,000 |
|
- |
|
| Duliege Anne-Marie |
Chief Medical Officer |
• – – |
2011-08-17 |
4 |
S |
$4.73 |
$25,050 |
D/D |
(5,296) |
24,704 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2011-08-15 |
4 |
S |
$4.50 |
$25,052 |
D/D |
(5,567) |
26,405 |
|
- |
|
| Laporte Kathleen |
Director |
– • – |
2011-07-01 |
4 |
S |
$6.83 |
$282,145 |
I/I |
(41,303) |
0 |
|
- |
|
| Laporte Kathleen |
Director |
– • – |
2011-06-30 |
4 |
S |
$6.90 |
$357,617 |
I/I |
(51,797) |
41,303 |
|
- |
|
| Laporte Kathleen |
Director |
– • – |
2011-06-28 |
4 |
S |
$7.03 |
$5,251,176 |
I/I |
(746,818) |
93,100 |
|
- |
|
| Duliege Anne-Marie |
Chief Medical Officer |
• – – |
2011-06-23 |
4 |
S |
$6.47 |
$26,029 |
D/D |
(4,023) |
30,000 |
|
- |
|
| Laporte Kathleen |
Director |
– • – |
2011-05-16 |
4 |
S |
$7.03 |
$50,131 |
I/I |
(7,131) |
839,918 |
|
- |
|
| Orwin John A |
CEO |
• • – |
2011-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
160,000 |
|
- |
|
| Laporte Kathleen |
Director |
– • – |
2011-01-14 |
4 |
S |
$7.01 |
$333,025 |
I/I |
(47,541) |
847,049 |
|
- |
|
| Laporte Kathleen |
Director |
– • – |
2011-01-13 |
4 |
S |
$7.01 |
$120,486 |
I/I |
(17,200) |
894,590 |
|
- |
|
| Laporte Kathleen |
Director |
– • – |
2011-01-12 |
4 |
S |
$7.09 |
$1,772,500 |
I/I |
(250,000) |
911,790 |
|
- |
|
| Laporte Kathleen |
Director |
– • – |
2011-01-11 |
4 |
S |
$7.22 |
$3,248,550 |
I/I |
(450,000) |
1,161,790 |
|
- |
|
| Laporte Kathleen |
Director |
– • – |
2011-01-10 |
4 |
S |
$7.54 |
$620,363 |
I/I |
(82,309) |
1,611,790 |
|
- |
|
| Cleveland Paul B |
EVP, Corp. Development and CFO |
• – – |
2010-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Venteicher Robert |
SVP, Technical Operations |
• – – |
2010-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
31,224 |
|
- |
|
| Duliege Anne-Marie |
Chief Medical Officer |
• – – |
2010-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Orwin John A |
President and COO |
• – – |
2010-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
60,000 |
|
- |
|
| Morris Arlene |
CEO |
• • – |
2010-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
75,000 |
|
- |
|
| Laporte Kathleen |
Director |
– • – |
2010-08-10 |
4 |
S |
$7.58 |
$608,333 |
I/I |
(80,308) |
1,694,099 |
|
- |
|
| Credit Suisse First Boston |
10% Owner |
– – • |
2010-08-09 |
4 |
S |
$7.83 |
$3,521,925 |
I/I |
(450,000) |
1,774,407 |
|
- |
|
| Laporte Kathleen |
Director |
– • – |
2010-08-09 |
4 |
S |
$7.83 |
$3,522,150 |
I/I |
(450,000) |
1,774,407 |
|
- |
|
225 Records found
|
|
Page 5 of 9 |
|
|
